Corporations Chiming In On Device Financings

Medical device corporations are getting involved in more venture capital financings.

With public market capitalizations sagging and venture capitalists hesitant to commit new capital, large publicly traded medical device companies were expected to feast on capital-starved device start-ups during this recession. However, this clearly hasn’t happened. If not for the $1.25 billion spent by Medtronic PLC for Medtronic Ablation Frontiers LLC, Medtronic CoreValve LLC and Ventor Technologies Ltd., the strategic acquisition market would be just as bleak as the market for initial public offerings of stock. [See Deal][See Deal][See Deal]

But the business development offices at Johnson & Johnson, St. Jude Medical Inc. and others have been busy....

Welcome to Scrip

Create an account to read this article

More from Strategy

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

More from Business

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.